SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zebra 365 who wrote (12403)7/31/1998 10:16:00 PM
From: Bradpalm1  Read Replies (1) of 23519
 
Zebra,

For starters, Leland lied to 'the street' and misled many powerful allies about production problems late last year. There's subsequently been a concerted effort by many these players to drive this stock down and punish this company. Add to this plummeting prescription numbers and a failure to exploit the expansion of the ED market by Viagra and it's not hard to understand and appreciate what the shorts essentially know.

As I said before, I wouldn't be short this stock now (the buyout rumors are currently too credible) but I personally wouldn't be long either. Scores still need to be settled and the road ahead is uncertain. The great hope for Vivus is that a large pharmaco will appreciate the conceptual benefits of the Muse 'delivery system' and purchase this company based on the future potential of transurethral drug administration. Leland is currently negotiating, however, from a position of tremendous weakness and will be lucky to get a buyout of over $14/share.

Bradpalm1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News